Skip to main content
. 2021 Feb 13;5(3):256–274. doi: 10.7150/ntno.51676

Figure 5.

Figure 5

(A) Blood clearance profile of 125I-labelled B16-BL6 sEVs, [125I]I-SAV (streptavidin construct), [125I]I-SAV-LA (streptavidin-lactadherin fusion protein), and [125I]I-IBB (biotin conjugated radiotracer) in healthy mice after iv. injection; data presented as mean ± standard error of means (SEM) of n = 4. (B) Ex vivo biodistribution of 125I-labelled B16-BL6 sEVs and [125I]I-IBB over 4 h post iv. injection; data presented as mean ± SEM of n = 4. Figure taken with permission from Morishita et al. 78 (C) Retention of intratumorally injected 125I-labelled B16-BL6 sEVs in tumor tissues of a xenograft mouse model with tumour volume of 100-200 or 300-500 mm3; data presented as mean ± SEM of n = 4. Figure adapted with permission from Matsumoto et al. 79 (D) In vivo biodistribution of 131I-labelled EVs (exo) isolated from 4T1 (mouse breast tumour) cells, HEK-293 (human embryonic kidney-293) cells, endothelial progenitor cells (EPC) and myeloid derived suppressor cells (MDSC) compared to free 131I biodistribution in tumour bearing mice. Figure adapted with permission from Rashid et al. 80.